Skip to main content

Advertisement

SpringerLink
Log in

Non-endoscopic Screening for Esophageal Squamous Cell Carcinoma: Recent Advances

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Esophageal squamous cell carcinoma (ESCC) is one of the most common tumors in the gastrointestinal tract, and China has a high incidence area with a high burden on the disease. As early symptoms of ESCC are not obvious, the mortality rate is high, and it is often diagnosed in the intermediate and advanced stages. However, early screening and treatment may reduce morbidity and mortality.

Methods

Screening methods are divided into endoscopic and non-endoscopic screening.

Results

Endoscopic screening cannot be widely used because of its invasive nature and high cost. Currently, non-endoscopic screening consists primarily of tumor biomarkers and cytology, and tumor biomarkers including autoantibodies, circulating tumor cells, circulating tumor DNA, exosomes and serum metabolomics are more likely to be effective. But the efficiency of early diagnosis of esophageal cancer is low and the accuracy of screening needs to be improved. The aim of this study is to summarize advances in non-endoscopic esophageal cancer screening and strategies to provide a scientific basis and research idea for esophageal cancer prevention and control.

Conclusions

Non-endoscopic screening is better than endoscopic screening. And the application of tumor biomarkers is much better than other non-endoscopic screening methods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

The data underlying this article are available in the article and in its online supplementary material.

References

  1. Murphy G, McCormack V, Abedi-Ardekani B, Arnold M, Camargo MC, Dar NA, Dawsey SM, Etemadi A, Fitzgerald RC, Fleischer DE, Freedman ND, Goldstein AM, Gopal S, Hashemian M, Hu N, Hyland PL, Kaimila B, Kamangar F, Malekzadeh R, Mathew CG, Menya D, Mulima G, Mwachiro MM, Mwasamwaja A, Pritchett N, Qiao YL, Ribeiro-Pinto LF, Ricciardone M, Schüz J, Sitas F, Taylor PR, Van Loon K, Wang SM, Wei WQ, Wild CP, Wu C, Abnet CC, Chanock SJ, Brennan P. International cancer seminars: a focus on esophageal squamous cell carcinoma. Ann Oncol. 2017;2086–93. https://doi.org/10.1093/annonc/mdx279.

  2. Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates From GLOBOCAN 2020. Gastroenterology. 2022;649–58. https://doi.org/10.1053/j.gastro.2022.05.054.

  3. Wild CP, Weiderpass E, Stewart BW. World Cancer Report: cancer research for cancer prevention. IARC Cancer. 2022. https://www.iarc.who.int/.

  4. Chen Q, Xu HF, Liu SZ, Guo LW, Cao XQ, Zheng LY, Sun XB, Zhang SK. Changing trend of incidence and mortality of esophageal cancer during 2010–2016 in Henan Province, China. Zhonghua Zhong Liu Za Zhi. 2022;86–92. https://doi.org/10.3760/cma.j.cn112152-20200605-00526.

  5. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;381–7. https://doi.org/10.1136/gutjnl-2014-308124.

  6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;394–424. https://doi.org/10.3322/caac.21492.

  7. Leng XF, Daiko H, Han YT, Mao YS. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma. Ann NY Acad Sci. 2020;213–24. https://doi.org/10.1111/nyas.14508.

  8. Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017;33–41. https://doi.org/10.20892/j.issn.2095-3941.2016.0093.

  9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;7–30. https://doi.org/10.3322/caac.21332.

  10. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;16–27. https://doi.org/10.1158/1055-9965.EPI-15-0578.

  11. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Li H, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Chen J, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;e555–67. https://doi.org/10.1016/S2214-109X(18)30127-X.

  12. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;1721–4. https://doi.org/10.1245/s10434-010-1024-1.

  13. Chen R, Liu Y, Song G, Li B, Zhao D, Hua Z, Wang X, Li J, Hao C, Zhang L, Liu S, Wang J, Zhou J, Zhang Y, Li B, Li Y, Feng X, Li L, Dong Z, Wei W, Wang G. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study. Gut. 2021;251–60. https://doi.org/10.1136/gutjnl-2019-320200.

  14. Pennathur A, Farkas A, Krasinskas AM, Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ, Luketich JD. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009;1048–55. https://doi.org/10.1016/j.athoracsur.2008.12.060.

  15. Ro TH, Mathew MA, Misra S. Value of screening endoscopy in evaluation of esophageal, gastric and colon cancers. World J Gastroenterol. 2015;9693–706. https://doi.org/10.3748/wjg.v21.i33.9693.

  16. Lao-Sirieix P, Fitzgerald RC. Screening for oesophageal cancer. Nat Rev Clin Oncol. 2012;278–87. https://doi.org/10.1038/nrclinonc.2012.35.

  17. Schmid E, Blaich E, Schwarzkopf H, Kovarik P. Diagnostic accuracy of fiber endoscopy in esophageal and gastric carcinoma. Attempt at error analysis. Z Gastroent. 1978;229–34. PMID: 654380.

  18. Qin Y, Taylor W, Bamlet WR, Ravindran A, Buglioni A, Cao X, Foote PH, Slettedahl SW, Mahoney DW, Albert PS, Kim S, Hu N, Taylor PR, Etemadi A, Sotoudeh M, Malekzadeh R, Abnet CC, Smyrk TC, Katzka D, Topazian MD, Dawsey SM, Ahlquist D, Kisiel JB, Iyer PG. Methylated DNA markers of esophageal squamous cancer and dysplasia: an international study. Cancer Epidemiol Biomarkers Prev. 2020;2642–50. https://doi.org/10.1158/1055-9965.EPI-20-0616.

  19. Zheng Q, Zhang L, Tu M, Yin X, Cai L, Zhang S, Yu L, Pan X, Huang Y. Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma. Clin Chim Acta. 2021;126–32. https://doi.org/10.1016/j.cca.2021.06.013.

  20. Yang Y, Huang X, Zhou L, Deng T, Ning T, Liu R, Zhang L, Bai M, Zhang H, Li H, Ba Y. Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma. BMC Cancer. 2019;526. https://doi.org/10.1186/s12885-019-5755-5.

  21. Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19–9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg. 2004;680–5. https://doi.org/10.1007/s00268-004-6865-y.

  22. Mroczko B, Kozłowski M, Groblewska M, Łukaszewicz M, Nikliński J, Jelski W, Laudański J, Chyczewski L, Szmitkowski M. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta. 2008;61–6. https://doi.org/10.1016/j.cca.2007.11.023.

  23. Sexauer D, Gray E, Zaenker P. Tumour- associated autoantibodies as prognostic cancer biomarkers- a review. Autoimmun Rev. 2022;103041. https://doi.org/10.1016/j.autrev.2022.103041.

  24. Xu YW, Peng YH, Xu LY, Xie JJ, Li EM. Autoantibodies: potential clinical applications in early detection of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma. World J Gastroenterol. 2019;5049–68. https://doi.org/10.3748/wjg.v25.i34.5049.

  25. Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, Chauhan AS, Kite TA, Maddison P, Robertson JF. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res. 2011;1474–80. https://doi.org/10.1158/1078-0432.CCR-10-1363.

  26. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol. 2006;513–9. PMID: 17409910.

  27. Heo CK, Bahk YY, Cho EW. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep. 2012;677–85. https://doi.org/10.5483/bmbrep.2012.45.12.236.

  28. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;6880–904. https://doi.org/10.1111/j.1742-4658.2009.07396.x.

  29. Chen WX, Hong XB, Hong CQ, Liu M, Li L, Huang LS, Xu LY, Xu YW, Peng YH, Li EM. Tumor-associated autoantibodies against fascin as a novel diagnostic biomarker for esophageal squamous cell carcinoma. Clin Res Hepatol Gastroenterol. 2017;327–32. https://doi.org/10.1016/j.clinre.2016.10.011.

  30. Peng YH, Xu YW, Guo H, Huang LS, Tan HZ, Hong CQ, Li SS, Xu LY, Li EM. Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma. Cancer Med. 2016;1388–96. https://doi.org/10.1002/cam4.702.

  31. Ren P, Ye H, Dai L, Liu M, Liu X, Chai Y, Shao Q, Li Y, Lei N, Peng B, Yao W, Zhang J. Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma. Oncol Rep. 2013;2297–303. https://doi.org/10.3892/or.2013.2714.

  32. Ye L, Guan S, Zhang C, Lee KH, Sun S, Wei J, Liu B. Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumour Biol. 2013;1873–7. https://doi.org/10.1007/s13277-013-0729-8.

  33. Zhou JH, Zhang B, Kernstine KH, Zhong L. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;1373–8. https://doi.org/10.3748/wjg.v17.i10.1373.

  34. Zhang JB, Cao M, Chen J, Ye SR, Xie K, He X, Ma XL, Zhang J, Yie SM. Serum anti-TOPO48 autoantibody as a biomarker for early diagnosis and prognosis in patients with esophageal squamous cell carcinoma. Clin Res Hepatol Gastroenterol. 2018;276–84. https://doi.org/10.1016/j.clinre.2017.09.007.

  35. Chen H, Sun G, Han Z, Wang H, Li J, Ye H, Song C, Zhang J, Wang P. Anti-CXCL8 autoantibody: a potential diagnostic biomarker for esophageal squamous cell carcinoma. Med Lith. 2022. https://doi.org/10.3390/medicina58101480.

  36. Sun G, Ye H, Wang X, Li T, Jiang D, Qiu C, Dai L, Shi J, Wang K, Song C, Wang P, Zhang J. Autoantibodies against tumor-associated antigens combined with microRNAs in detecting esophageal squamous cell carcinoma. Cancer Med. 2020;1173–82. https://doi.org/10.1002/cam4.2792.

  37. Li L, Zhang L, Montgomery KC, Jiang L, Lyon CJ, Hu TY. Advanced technologies for molecular diagnosis of cancer: state of pre-clinical tumor-derived exosome liquid biopsies. Mater Today Bio. 2023;100538. https://doi.org/10.1016/j.mtbio.2022.100538.

  38. Mandel P, Metais P. Nuclear acids in human blood plasma. CR Seances Soc Biol Fil. 1948;241–3. PMID: 18875018.

  39. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer–a survey. Biochim Biophys Acta. 2007;181–232. https://doi.org/10.1016/j.bbcan.2006.10.001.

  40. Chu LY, Peng YH, Weng XF, Xie JJ, Xu YW. Blood-based biomarkers for early detection of esophageal squamous cell carcinoma. World J Gastroenterol. 2020;1708–25. https://doi.org/10.3748/wjg.v26.i15.1708.

  41. De Rubis G, Rajeev KS, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;172–86. https://doi.org/10.1016/j.tips.2019.01.006.

  42. Spindler KL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS ONE. 2015;e108247. https://doi.org/10.1371/journal.pone.0108247.

  43. Lima SC, Hernández-Vargas H, Simão T, Durand G, Kruel CD, Le Calvez-Kelm F, Ribeiro PLF, Herceg Z. Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. Epigenetics. 2011;1217–27. https://doi.org/10.4161/epi.6.10.17199.

  44. Lin DC, Wang MR, Koeffler HP. Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients. Gastroenterology. 2018;374–89. https://doi.org/10.1053/j.gastro.2017.06.066.

  45. Yu Q, Xia N, Zhao Y, Jin H, Chen R, Ye F, Chen L, Xie Y, Wan K, Zhou J, Zhou D, Lv X. Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection. BMC Med Genomics. 2022;247. https://doi.org/10.1186/s12920-022-01401-x.

  46. Fan Z, Qin Y, Zhou J, Chen R, Gu J, Li M, Zhou J, Li X, Lin D, Wang J, Deng D, Wei W. Feasibility of using P16 methylation as a cytologic marker for esophageal squamous cell carcinoma screening: a pilot study. Cancer Med. 2022;4033–42. https://doi.org/10.1002/cam4.4718.

  47. Ke X, Xiong X, Lin Y, Zhang H. Chimeric RNA and exosomes-based liquid biopsy. Methods Mol Biol. 2020;211–8. https://doi.org/10.1007/978-1-4939-9904-0_16.

  48. Li K, Lin Y, Luo Y, Xiong X, Wang L, Durante K, Li J, Zhou F, Guo Y, Chen S, Chen Y, Zhang D, Yeung SJ, Zhang H. A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study. Mol Cancer. 2022;21. https://doi.org/10.1186/s12943-022-01499-8.

  49. Niu L, Song X, Wang N, Xue L, Song X, Xie L. Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer. Cancer Sci. 2019;433–42. https://doi.org/10.1111/cas.13862.

  50. Ju S, Chen C, Zhang J, Xu L, Zhang X, Li Z, Chen Y, Zhou J, Ji F, Wang L. Detection of circulating tumor cells: opportunities and challenges. Biomark Res. 2022;58. https://doi.org/10.1186/s40364-022-00403-2.

  51. Li X, Wang Y, Wang Q, Liu Y, Bao W, Wu S. Exosomes in cancer: small transporters with big functions. Cancer Lett. 2018;55–65. https://doi.org/10.1016/j.canlet.2018.07.037.

  52. Li F, Kaczor-Urbanowicz KE, Sun J, Majem B, Lo HC, Kim Y, Koyano K, Rao SL, Kang SY, Kim SM, Kim KM, Kim S, Chia D, Elashoff D, Grogan TR, Xiao X, Wong DTW. Characterization of human salivary extracellular RNA by next-generation sequencing. Clin Chem. 2018;1085–95. https://doi.org/10.1373/clinchem.2017.285072.

  53. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res. 2012;10937–49. https://doi.org/10.1093/nar/gks832.

  54. Jia S, Zhang Q, Wang Y, Wang Y, Liu D, He Y, Wei X, Gu H, Ma W, Luo W, Yuan Z. PIWI-interacting RNA sequencing profiles in maternal plasma-derived exosomes reveal novel non-invasive prenatal biomarkers for the early diagnosis of nonsyndromic cleft lip and palate. EBioMedicine. 2021;103253. https://doi.org/10.1016/j.ebiom.2021.103253.

  55. Zhu L, Li J, Gong Y, Wu Q, Tan S, Sun D, Xu X, Zuo Y, Zhao Y, Wei YQ, Wei XW, Peng Y. Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis. Mol Cancer. 2019;74. https://doi.org/10.1186/s12943-019-1000-8.

  56. Xie K, Zheng C, Gu W, Jiang Z, Luo C, Luo J, Diao Y, Wang G, Cong Z, Yao X, Hu L, Shen Y. A RASSF8-AS1 based exosomal lncRNAs panel used for diagnostic and prognostic biomarkers for esophageal squamous cell carcinoma. Thorac Cancer. 2022;3341–52. https://doi.org/10.1111/1759-7714.14690.

  57. Miyoshi J, Zhu Z, Luo A, Toden S, Zhou X, Izumi D, Kanda M, Takayama T, Parker IM, Wang M, Gao F, Zaidi AH, Baba H, Kodera Y, Cui Y, Wang X, Liu Z, Goel A. A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study. Mol Cancer. 2022;44. https://doi.org/10.1186/s12943-022-01507-x.

  58. Kahng DH, Kim GH, Park SJ, Kim S, Lee MW, Lee BE, H. I. MicroRNA Expression in plasma of esophageal squamous cell carcinoma patients. J Korean Med Sci. 2022;e197. https://doi.org/10.3346/jkms.2022.37.e197.

  59. Kim S, Kim GH, Park SJ, Kwon CH, I H, Lee MW, Lee BE. Exosomal MicroRNA analyses in esophageal squamous cell carcinoma cell lines. J Clin Med. 2022. https://doi.org/10.3390/jcm11154426.

  60. Rong J, Wang Q, Zhang Y, Zhu D, Sun H, Tang W, Wang R, Shi W, Cao XF. Circ-DLG1 promotes the proliferation of esophageal squamous cell carcinoma. OncoTargets Ther. 2018;6723–30. https://doi.org/10.2147/OTT.S175826.

  61. Ibuki Y, Nishiyama Y, Tsutani Y, Emi M, Hamai Y, Okada M, Tahara H. Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. PLoS ONE. 2020;e231116. https://doi.org/10.1371/journal.pone.0231116.

  62. Zhang L, Dong B, Ren P, Ye H, Shi J, Qin J, Wang K, Wang P, Zhang J. Circulating plasma microRNAs in the detection of esophageal squamous cell carcinoma. Oncol Lett. 2018;3303–18. https://doi.org/10.3892/ol.2018.8995.

  63. Lin Y, Dong H, Deng W, Lin W, Li K, Xiong X, Guo Y, Zhou F, Ma C, Chen Y, Ren H, Yang H, Dai N, Ma L, Meltzer SJ, Yeung SJ, Zhang H. Evaluation of salivary exosomal chimeric GOLM1-NAA35 RNA as a potential biomarker in esophageal carcinoma. Clin Cancer Res. 2019;3035–45. https://doi.org/10.1158/1078-0432.CCR-18-3169.

  64. Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer. Mol Ther Nucleic Acids. 2019;118–29. https://doi.org/10.1016/j.omtn.2019.02.005.

  65. Li P, Chen S, Chen H, Mo X, Li T, Shao Y, Xiao B, Guo J. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta. 2015;132–6. https://doi.org/10.1016/j.cca.2015.02.018.

  66. Hu X, Wu D, He X, Zhao H, He Z, Lin J, Wang K, Wang W, Pan Z, Lin H, Wang M. circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling. Mol Cancer. 2019;160. https://doi.org/10.1186/s12943-019-1095-y.

  67. Cobanoğlu U, Dülger C, Kemik O, Celik S, Sayir F. A novel screening test for esophageal squamous cell carcinoma: sirtuin-3. Eur Rev Med Pharmacol Sci. 2017;5399–401. https://doi.org/10.26355/eurrev_201712_13926.

  68. Wang X, Lai M, Wang Y, Chai R, Li N, Ou L, Zheng K, Li J, Xu G, Wang S, Dong Y, Wang S. Upregulation of centromere proteins as potential biomarkers for esophageal squamous cell carcinoma diagnosis and prognosis. Biomed Res Int. 2022;3758731. https://doi.org/10.1155/2022/3758731.

  69. Zheng L, Li L, Xie J, Jin H, Zhu N. Six novel biomarkers for diagnosis and prognosis of esophageal squamous cell carcinoma: validated by scRNA-seq and qPCR. J Cancer. 2021;899–911. https://doi.org/10.7150/jca.50443.

  70. Zhang S, Lu X, Hu C, Li Y, Yang H, Yan H, Fan J, Xu G, Abnet CC, Qiao Y. Serum metabolomics for biomarker screening of esophageal squamous cell carcinoma and esophageal squamous dysplasia using gas chromatography-mass spectrometry. ACS Omega. 2020;26402–12. https://doi.org/10.1021/acsomega.0c02600.

  71. Zhu Q, Huang L, Yang Q, Ao Z, Yang R, Krzesniak J, Lou D, Hu L, Dai X, Guo F, Liu F. Metabolomic analysis of exosomal-markers in esophageal squamous cell carcinoma. Nanoscale. 2021;16457–64. https://doi.org/10.1039/d1nr04015d.

  72. Zhu S, Liu J, Min L, Sun X, Guo Q, Li H, Zhang Z, Zhao Y, Gu J, Zhang S. Cadherin expression shift could well distinguish esophageal squamous cell carcinoma from non- cancerous esophageal tissues. Oncol Res Treat. 2018;380–5. https://doi.org/10.1159/000487267.

  73. Shesh PM, Sadegh S, Khajeniazi N, Behnampour MR, Kalani AM, Marjani A. MicroRNA-146a as a prognostic biomarker for esophageal squamous cell carcinoma. Cancer Manag Res. 2020;973–80. https://doi.org/10.2147/CMAR.S229397.

  74. Codipilly DC, Qin Y, Dawsey SM, Kisiel J, Topazian M, Ahlquist D, Iyer PG. Screening for esophageal squamous cell carcinoma: recent advances. Gastrointest Endosc. 2018;413–26. https://doi.org/10.1016/j.gie.2018.04.2352.

  75. Middleton DRS, Mmbaga BT, O’Donovan M, Abedi-Ardekani B, Debiram-Beecham I, Nyakunga-Maro G, Maro V, Bromwich M, Daudi A, Ngowi T, Minde R, Claver J, Mremi A, Mwasamwaja A, Schüz J, Fitzgerald RC, McCormack V. Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. Int J Cancer. 2021;1208–18. https://doi.org/10.1002/ijc.33366.

  76. Lao-Sirieix P, Boussioutas A, Kadri SR, O’Donovan M, Debiram I, Das M, Harihar L, Fitzgerald RC. Non-endoscopic screening biomarkers for Barrett’s oesophagus: from microarray analysis to the clinic. Gut. 2009;1451–9. https://doi.org/10.1136/gut.2009.180281.

  77. Tang YY, Wang JS. Exploration of sponge cytology used for esophageal cancer screening. J Med Theor Prac. 2022. https://doi.org/10.19381/j.issn.1001-7585.2022.11.011

  78. Pan QJ, Roth MJ, Guo HQ, Kochman ML, Wang GQ, Henry M, Wei WQ, Giffen CA, Lu N, Abnet CC, Hao CQ, Taylor PR, Qiao YL, Dawsey SM. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Llinxian. China Acta Cytol. 2008;14–23. https://doi.org/10.1159/000325430.

  79. Yang CS. Research on esophageal cancer in China: a review. Cancer Res. 1980;2633–44. PMID: 6992989.

  80. Wang G, Uo QG, We NQ, Ia WEI, Yo GQ, U-lin IAO. The practice and experience of screening and early detection for esophageal cancer. Chin Tumor. 2010;4–8. 80-https://kns.cnki.net/kcms2/article/abstract?v=xzY5Ip_ThcntrQlvGNMbpcaTJ4sFKuUNyPiMFFWXeD4oK4VtkrOWx7LGPyni06ZRXNH0oypYi1Vn9zc-4cpTdffqJRNrFuEDjLBuW57W99RnxzSZ9PHWt3G4N_TuV4o9UHBosTsF0Y=&uniplatform=NZKPT&language=CHS. ISSN: 1004-0242

  81. Feng Y, Liang Y, Yao B, Xu J, Zang J, Zhang Y, Zhang J, Xu G, Wei B, Yao X, Huang P, Shi R. A rapid cytological screening as pre-endoscopy screening for early esophageal squamous cell lesions: a prospective pilot study from a Chinese Academic Center. Technol Cancer Res Treat. 2022;2091159208. https://doi.org/10.1177/15330338211066200.

  82. Roshandel G, Merat S, Sotoudeh M, Khoshnia M, Poustchi H, Lao-Sirieix P, Malhotra S, O’Donovan M, Etemadi A, Nickmanesh A, Pourshams A, Norouzi A, Debiram I, Semnani S, Abnet CC, Dawsey SM, Fitzgerald RC, Malekzadeh R. Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. Br J Cancer. 2014;2235–41. https://doi.org/10.1038/bjc.2014.506.

  83. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, Lovat L, Griffin M, Ragunath K, Haidry R, Sami SS, Kaye P, Novelli M, Disep B, Ostler R, Aigret B, North BV, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Sasieni PD, Fitzgerald RC. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med. 2015;e1001780. https://doi.org/10.1371/journal.pmed.1001780.

  84. Paterson AL, Gehrung M, Fitzgerald RC, O’Donovan M. Role of TFF3 as an adjunct in the diagnosis of Barrett’s esophagus using a minimally invasive esophageal sampling device-the Cytosponge (TM). Diagn Cytopathol. 2020;253–64. https://doi.org/10.1002/dc.24354.

  85. Sonoda H, Kohnoe S, Yamazato T, Satoh Y, Morizono G, Shikata K, Morita M, Watanabe A, Morita M, Kakeji Y, Inoue F, Maehara Y. Colorectal cancer screening with odour material by canine scent detection. Gut. 2011;814–9. https://doi.org/10.1136/gut.2010.218305.

  86. Zou X, Zhou W, Lu Y, Shen C, Hu Z, Wang H, Jiang H, Chu Y. Exhaled gases online measurements for esophageal cancer patients and healthy people by proton transfer reaction mass spectrometry. J Gastroenterol Hepatol. 2016;1837–43. https://doi.org/10.1111/jgh.13380.

  87. Song S, Lei L, Zhang R, Li H, Peng J, Chen WQ, Ren JS. Research progress on screening for esophageal cancer. Chin J Cancer Prev Treat. 2022. https://doi.org/10.16073/j.cnki.cjcpt.2022.07.01

  88. Sekiguchi M, Terauchi T, Kakugawa Y, Shimada N, Saito Y, Matsuda T. Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening. World J Gastroenterol. 2017;2743–9. https://doi.org/10.3748/wjg.v23.i15.2743.

  89. Li H, Ding C, Zeng H, Zheng R, Cao M, Ren J, Shi J, Sun D, He S, Yang Z, Yu Y, Zhang Z, Sun X, Guo G, Song G, Wei W, Chen W, He J. Improved esophageal squamous cell carcinoma screening effectiveness by risk-stratified endoscopic screening: evidence from high-risk areas in China. Cancer Commun. 2021;715–25. https://doi.org/10.1002/cac2.12186.

  90. Sanford NN, Mahal BA, Royce TJ, Pike LRG, Hwang WL. Sex disparity and copy number alterations in esophageal squamous cell carcinoma. Clin Gastroenterol Hepatol. 2019;1207–9. https://doi.org/10.1016/j.cgh.2018.08.026.

Download references

Acknowledgements

We thank all the authors for their word with this manuscript, and we all agreed with the content of the manuscript.

Funding

Major cultivation project of Education Department of Sichuan Province, NO. 18CZ0044.

Author information

Author notes

  1. Tao Yin and Xingwang Sun are co-corresponding authors.

Authors and Affiliations

  1. School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China

    Xiao Mou

  2. College of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China

    Zhenglin Peng, Tao Yin & Xingwang Sun

  3. Department of Pathology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

    Tao Yin & Xingwang Sun

Authors
  1. Xiao Mou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhenglin Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xingwang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Xiao Mou: Investigation, data curation, writing the original manuscript; Zhenglin Peng: data analysis; Tao Yin: Conceptualization, reviewing and editing of the final manuscript; Xingwang Sun: Supervision and reviewing the manuscript.

Corresponding author

Correspondence to Xiao Mou.

Ethics declarations

Ethics Approval and Consent to Participate

This article does not contain any studies with human participants or animals performed by any of the authors.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mou, X., Peng, Z., Yin, T. et al. Non-endoscopic Screening for Esophageal Squamous Cell Carcinoma: Recent Advances. J Gastrointest Canc 55, 118–128 (2024). https://doi.org/10.1007/s12029-023-00980-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-023-00980-x

Keywords

Search

Navigation